Drug Resistance Assays For Mycobacterium Tuberculosis
ANTIMICROBIAL DRUG RESISTANCE, VOL 2: CLINICAL AND EPIDEMIOLOGICAL ASPECTS(2009)
摘要
The introduction of antimicrobial therapy of tuberculosis during the second half of the last century was a turning point in
the millennium-old history of this disease. However, the problem of drug resistance emerged, and with it, two levels of concern.
First, such resistance not only poses a public health threat to successful control of TB epidemics, but it also complicates
the approach to treatment of individual patients. In previous reviews we have addressed the history of research and evolution
of views based on these studies regarding the usefulness of drug susceptibility testing (1, 2). Historically, most skepticism
regarding the need for drug susceptibility testing was related to the period before introduction of rifampin (RMP) and pyrazinamide
(PZA). It often referred to the inability of laboratories to provide test results rapidly enough for the information to be
used to adjust treatment regimens in a timely manner. In 1990, the American Thoracic Society (ATS) and the CDC published the
following statement, “Given the low prevalence of drug-resistant Mycobacterium tuberculosis (MTBC) in most parts of the United States, the cost of routine testing of all initial isolates is diffi cult to justify”
(3).
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要